News & Events

In this section

Beijing Union Purchases Instem's Preclinical Software Solution

Chinese Contract Research Organization selects Provantis integrated preclinical software solution to automate study processes

CONSHOHOCKEN, PA - (BUSINESS WIRE) - January 31, 2012 - - Instem, a leading provider of early development software applications, announced today that Beijing Union – Genius Pharmaceutical Technology Ltd (Beijing Union) has purchased the Provantis preclinical software solution following a comprehensive competitive evaluation of domestic and western solutions on the market.
 
Beijing Union, located in the Beijing Economic Technological Development Area, was established in 2002 as a commercial offshoot of the Chinese Academy of Medical Sciences and Peking Union Medical College. The company carries out a range of new drug safety evaluation studies in compliance with Good Laboratory Practices (GLPs), including acute, chronic and carcinogenicity studies, genetic toxicity, reproductive  toxicity, safety pharmacology, local toxicity, immunotoxicity, dermal toxicity testing and toxicokinetics studies.

Key Facts

  • Integrated Reproductive and Inlife Toxicology modules purchased for implementation at Beijing facility
  • Competitive evaluation conducted; Instem selected for local presence within the region combined with global market leadership
  • Implementation begins immediately; project underway
  • Provantis offers Beijing Union compliance to national and western standards and dual language operation
  • Beijing Union to be supported from Instem’s full service office in Zhangjiang Hi-Tech Park, Shanghai

Dr. Aiping Wang, Director, Beijing Union commented “We were looking for a world class solution that would help us to further improve the quality of our study processes and deliver demonstrable efficiency improvements. I am pleased to say that following a thorough review of local and Western software products on the market we are confident that Instem and Provantis are the right choices. We are looking forward to building a long and successful partnership with Instem for the future.”

Neil Donaldson, VP of European & Asian Operations, Instem said “We are delighted to welcome Beijing Union to our growing client base within China and are looking forward to working closely with them so they can quickly realize the benefits of Provantis.”

As the first western toxicology/pathology software supplier to enter the Chinese market, Instem officially deployed its first China-based system in one of the largest and most advanced vivariums during 2006. Acknowledging analyst projections that the People’s Republic of China (PRC) is growing to become the second largest pharmaceutical market in the world, Instem established a full-service office in Shanghai, recruited local staff and has localized the Provantis product suite into Mandarin Chinese. Instem is supporting international organizations and domestic laboratories exclusively serving the PRC.

About Beijing Union

Beijing Union-Genius Pharmaceutical Technology Ltd (New Drug Safety Evaluation Centre in CAMS & PUMC) is recognized as a contract research organization (CRO) engaged in the safety evaluation of services, certified by SFDA GLP, US AAALAC, ISO9001:2008, China Metrology Accreditation, UKAS and ANAB. It mainly carries out a range of  safety evaluation studies for new drugs, new chemistry, chemicals and pesticides in compliance with Good Laboratory Practices (GLP), including single dose toxicity (rodents and non-rodents), repeated dose toxicity (rodents and non-rodents), reproductive toxicity, genetic toxicity (Ames, micronucleus, chromosomal aberrations), carcinogenicity, local toxicity, immunogenicity, safety pharmacology and  toxicokinetics studies.

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

Meeting clients at the intersection of investment & return™.

Press Contacts:

Instem
Gary Mitchell (US HQ)
gary.mitchell@instem.com
Tel: 610-941-0990

Julie Jones (UK HQ)
julie.jones@instem.com
Tel: +44 (0) 1785 825600